EE668 Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment for Adults and Adolescents Aged 12 Years and Older With Resected Stage IIB/IIC Melanoma in France
Abstract
Authors
P. Saiag N. Meyer S. Zhang R. Jiang C. Mamane O. Chaker L. Bensimon A. Babonneau R. Hidra L. Rey S. Leproust A. Rai D. Vohra G. Khatri G. de Pouvourville